Related Experiment Videos
Protective effect of a new anti-asthmatic agent (Minocromil) in bronchial allergen challenge tests
Abstract:
Ten patients were included in a double-blind crossover trial, designed to compare the effects of a new anti-asthmatic agent Minocromil, an organic decarboxylic acid, and placebo on bronchial allergen challenge. The challenges were performed at weekly intervals. Significant differences in favour of Minocromil were found in the concentration of antigen reached at which FEV1 fell below 20% of baseline. This was confirmed by analysis of the decrease in FEV1 recorded at the highest concentrations of antigens, which showed statistically significant differences in favour of Minocromil.
Insights
Minocromil, a new anti-asthmatic drug, demonstrated significant benefits in a clinical trial. It improved lung function in asthma patients challenged with allergens compared to placebo.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Asthma management requires effective bronchodilators.
- Allergen challenges are used to assess asthma exacerbations.
Purpose of the Study:
- To evaluate the efficacy of Minocromil against placebo.
- To assess the impact of Minocromil on allergen-induced bronchoconstriction.
Main Methods:
- Double-blind, placebo-controlled, crossover trial.
- Ten asthma patients underwent weekly bronchial allergen challenges.
- Evaluated forced expiratory volume in 1 second (FEV1) changes.
Main Results:
- Minocromil significantly increased the antigen concentration threshold for a 20% FEV1 drop.
- Statistically significant improvements in FEV1 were observed with Minocromil.
- Reduced FEV1 decrease at highest antigen doses favored Minocromil.
Conclusions:
- Minocromil shows significant bronchodilarory effects in asthma.
- The new anti-asthmatic agent Minocromil offers a promising therapeutic option.